Please assess the completion status of the following clinical trial:

Trial Title: Bevacizumab in Metastatic Renal Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed advanced and/or metastatic renal cell cancer~* No contraindications for Avastin according to summary of product characteristics (SmPC)~Exclusion Criteria:~-

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Advanced and/or Metastatic RCC participants (Type: None): Participants with mRCC who are being treated with bevacizumab at the recommended dose of 10 milligram per kilogram (mg/kg) of body weight once every 2 weeks as an intravenous infusion, in combination with interferon alpha-2a at the recommended starting dose of 9 million international units (MIU) 3 times a week until disease progression will be observed. No diagnostic or therapeutic interventions will be given other than used in normal daily routine.

Based on this trial design, predict the completion outcome and termination type (if applicable).